These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37336827)

  • 1. The quantification of circular RNA 0007841 during induction therapy helps estimate the response and survival benefits to bortezomib-based regimen in multiple myeloma.
    Guo Y; Feng X; Wang Z; Zhang R; Zheng K; Xu J; Hu P; Zhang R
    Ir J Med Sci; 2024 Feb; 193(1):17-25. PubMed ID: 37336827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell division cycle 37 change after bortezomib-based induction therapy helps to predict clinical response and prognosis in multiple myeloma patients.
    Lin W; Chen X; Zheng H; Cai Z
    Hematology; 2023 Dec; 28(1):2231741. PubMed ID: 37409850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
    Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
    Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
    Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
    Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple.
    Schütz NP; Ochoa P; Duarte P; Remaggi G; Yantorno S; Corzo A; Zabaljauregui S; Shanley C; Lopresti S; Orlando S; Verri V; Quiroga L; García CA; Fernández V; Fantl D
    Hematol Oncol; 2020 Aug; 38(3):363-371. PubMed ID: 32196120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.
    Sidana S; Kumar S; Fraser R; Estrada-Merly N; Giralt S; Agrawal V; Anderson LD; Aljurf M; Banerjee R; Bashey A; Battiwalla M; Beitinjaneh A; Chakraborty R; Chhabra S; Dhakal B; Dholaria B; Hashmi S; Janakiram M; Lee C; Lekakis L; Murthy HS; Parrondo R; Wangjam T; Usmani S; Shah N; Qazilbash M; D'Souza A
    Transplant Cell Ther; 2022 Feb; 28(2):83.e1-83.e9. PubMed ID: 34781066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circular RNA SPI1 expression before and after induction therapy and its correlation with clinical features, treatment response, and survival of acute myeloid leukemia patients.
    Xiong T; Xia L; Song Q
    J Clin Lab Anal; 2023 Feb; 37(3):e24835. PubMed ID: 36644997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
    Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
    Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A cohort study comparing the efficacy and safety of bortezomib plus dexamethasone versus bortezomib, epirubicin and dexamethasone in patients with multiple myeloma].
    Hao QY; Chen H; Liu KY; Wen L; Huang XJ; Lu J
    Zhonghua Nei Ke Za Zhi; 2016 Sep; 55(9):689-94. PubMed ID: 27586976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysregulated circular RNAs are closely linked to multiple myeloma prognosis, with circ_0026652 predicting bortezomib‑based treatment response and survival via the microRNA‑608‑mediated Wnt/β‑catenin pathway.
    Li L; Liu J; Du J; Jiang H; He H; Lu J; Qiang W; Hou N; Guo P; Zhuang Y; Fu W
    Oncol Rep; 2022 Nov; 48(5):. PubMed ID: 36129153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein Kinase D 1 Predicts Poor Treatment Response and Unfavorable Survival of Bortezomib-Based Treatment, and Its Knockdown Enhances Drug Sensitivity to Bortezomib in Multiple Myeloma.
    Li X; Yang Y; Yi X
    Technol Cancer Res Treat; 2020; 19():1533033820936770. PubMed ID: 32799769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma.
    Lee YJ; Moon JH; Sohn SK; Kim SJ; Jung SH; Lee JJ; Jo JC; Shin HJ; Lee WS; Lee JH; Bae SH; Kim MK; Lee HS; Kim K; Min CK;
    Bone Marrow Transplant; 2019 Dec; 54(12):2051-2059. PubMed ID: 31358918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide with dexamethasone to multiple myeloma patients relapsing from bortezomib-based induction therapies: A prospective, observational study.
    Tan TD; Hong YC; Li SS; Yu JT; Sung YC; Wang PN; Teng CJ
    Chin J Physiol; 2020; 63(5):211-217. PubMed ID: 33109787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cyclophosphamide-thalidomide-dexamethasone to bortezomib-cyclophosphamide-dexamethasone as induction therapy for multiple myeloma patients in Brazil.
    Vigolo S; Zuckermann J; Bittencourt RI; Silla L; Pilger DA
    Hematol Oncol Stem Cell Ther; 2017 Sep; 10(3):135-142. PubMed ID: 28636891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circular RNA circ-CCT3 promotes bortezomib resistance in multiple myeloma via modulating miR-223-3p/BRD4 axis.
    Liu D; Wang Y; Li H; Peng S; Tan H; Huang Z
    Anticancer Drugs; 2022 Jan; 33(1):e145-e154. PubMed ID: 34387610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study.
    Huang BT; Tan Y; Zhao WH; Zeng QC; Li BS; Chen RL
    J Cancer Res Clin Oncol; 2014 Feb; 140(2):303-9. PubMed ID: 24337419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.